159 related articles for article (PubMed ID: 26745766)
41. Pharmacological Characterization of a Potent Inhibitor of Autotaxin in Animal Models of Inflammatory Bowel Disease and Multiple Sclerosis.
Thirunavukkarasu K; Tan B; Swearingen CA; Rocha G; Bui HH; McCann DJ; Jones SB; Norman BH; Pfeifer LA; Saha JK
J Pharmacol Exp Ther; 2016 Oct; 359(1):207-14. PubMed ID: 27516465
[TBL] [Abstract][Full Text] [Related]
42. Autotaxin in embryonic development.
Moolenaar WH; Houben AJ; Lee SJ; van Meeteren LA
Biochim Biophys Acta; 2013 Jan; 1831(1):13-9. PubMed ID: 23022664
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors.
Pantsar T; Singha P; Nevalainen TJ; Koshevoy I; Leppänen J; Poso A; Niskanen JMA; Pasonen-Seppänen S; Savinainen JR; Laitinen T; Laitinen JT
Eur J Pharm Sci; 2017 Sep; 107():97-111. PubMed ID: 28687529
[TBL] [Abstract][Full Text] [Related]
44. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
45. Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes.
Lanier M; Cole DC; Istratiy Y; Klein MG; Schwartz PA; Tjhen R; Jennings A; Hixon MS
J Med Chem; 2017 Jun; 60(12):5209-5215. PubMed ID: 28564542
[TBL] [Abstract][Full Text] [Related]
46. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.
Teo K; Brunton VG
Biochem J; 2014 Oct; 463(1):157-65. PubMed ID: 25195735
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
48. Expression of autotaxin and acylglycerol kinase in proliferative vitreoretinal epiretinal membranes.
Abu El-Asrar AM; Missotten L; Geboes K
Acta Ophthalmol; 2012 Mar; 90(2):e84-9. PubMed ID: 22103573
[TBL] [Abstract][Full Text] [Related]
49. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
Tabuchi S
Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
[TBL] [Abstract][Full Text] [Related]
50. Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis.
Jiang N; Zhou Y; Zhu M; Zhang J; Cao M; Lei H; Guo M; Gong P; Su G; Zhai X
Eur J Med Chem; 2020 Feb; 187():111904. PubMed ID: 31806537
[TBL] [Abstract][Full Text] [Related]
51. Decrease in circulating autotaxin by oral administration of prednisolone.
Sumida H; Nakamura K; Yanagida K; Ohkawa R; Asano Y; Kadono T; Tamaki K; Igarashi K; Aoki J; Sato S; Ishii S; Shimizu T; Yatomi Y
Clin Chim Acta; 2013 Jan; 415():74-80. PubMed ID: 23063960
[TBL] [Abstract][Full Text] [Related]
52. [Function and biological activities of the autotaxin-LPA axis].
Li ZW; Zhao YR; Zhao C; Fu R; Li ZY
Sheng Li Xue Bao; 2011 Dec; 63(6):601-10. PubMed ID: 22193457
[TBL] [Abstract][Full Text] [Related]
53. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
Orosa B; García S; Conde C
Eur J Pharmacol; 2015 Oct; 765():228-33. PubMed ID: 26297977
[TBL] [Abstract][Full Text] [Related]
54. Autotaxin-LPA axis regulates hMSC migration by adherent junction disruption and cytoskeletal rearrangement via LPAR1/3-dependent PKC/GSK3β/β-catenin and PKC/Rho GTPase pathways.
Ryu JM; Han HJ
Stem Cells; 2015 Mar; 33(3):819-32. PubMed ID: 25376707
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: use of a conformation-based hypothesis to facilitate compound design.
Walker DP; Arhancet GB; Lu HF; Heasley SE; Metz S; Kablaoui NM; Franco FM; Hanau CE; Scholten JA; Springer JR; Fobian YM; Carter JS; Xing L; Yang S; Shaffer AF; Jerome GM; Baratta MT; Moore WM; Vazquez ML
Bioorg Med Chem Lett; 2013 Feb; 23(4):1120-6. PubMed ID: 23298810
[TBL] [Abstract][Full Text] [Related]
56. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.
van Meeteren LA; Ruurs P; Stortelers C; Bouwman P; van Rooijen MA; Pradère JP; Pettit TR; Wakelam MJ; Saulnier-Blache JS; Mummery CL; Moolenaar WH; Jonkers J
Mol Cell Biol; 2006 Jul; 26(13):5015-22. PubMed ID: 16782887
[TBL] [Abstract][Full Text] [Related]
57. Structure-activity relationship for aryl and heteroaryl boronic acid inhibitors of hormone-sensitive lipase.
Ebdrup S; Jacobsen P; Farrington AD; Vedsø P
Bioorg Med Chem; 2005 Mar; 13(6):2305-12. PubMed ID: 15727879
[TBL] [Abstract][Full Text] [Related]
58. Suppression of metastasis of intravenously-inoculated B16/F10 melanoma cells by the novel ginseng-derived ingredient, gintonin: involvement of autotaxin inhibition.
Hwang SH; Lee BH; Kim HJ; Cho HJ; Shin HC; Im KS; Choi SH; Shin TJ; Lee SM; Nam SW; Kim HC; Rhim H; Nah SY
Int J Oncol; 2013 Jan; 42(1):317-26. PubMed ID: 23174888
[TBL] [Abstract][Full Text] [Related]
59. Structure-based linker exploration: Discovery of 1-ethyl-1H-indole analogs as novel ATX inhibitors.
Jia F; Lei H; Chen Y; Li T; Xing L; Cao Z; Zhai X
Bioorg Med Chem; 2020 Nov; 28(22):115795. PubMed ID: 33032188
[TBL] [Abstract][Full Text] [Related]
60. Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif.
Fells JI; Lee SC; Norman DD; Tsukahara R; Kirby JR; Nelson S; Seibel W; Papoian R; Patil R; Miller DD; Parrill AL; Pham TC; Baker DL; Bittman R; Tigyi G
FEBS J; 2014 Feb; 281(4):1017-28. PubMed ID: 24314137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
